RxDoctor Payments DataLook up a doctor →

Christopher Evans, MD

Urology · Reno, NVNPI 1356326060

Payments from drug & device makers

$2,773,136in general payments, 2019–2025

Across 406 payments — averaging $6830.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medivation LLC.$1.9M
  • Janssen Research & Development, LLC$452K
  • Pfizer$130K
  • Astellas Pharma Global Development$104K
  • Johnson & Johnson$68K
  • Astellas Pharma Inc$32K
  • plus $47K from 11 others
$6,276in research payments, 2019–2025

Across 10 payments — averaging $627.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$4K
  • Astellas Pharma Global Development$2K

What the payments were for

  • Consulting fees$61,80534%
  • Speaking & faculty fees$84,47046%
  • Travel & lodging$34,22119%
  • Food & beverage$3,6402%
  • Education$350%
  • Gifts$900%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,773,136 in reported general payments places this provider in the 95th percentile of 63 urology providers in Nevada.

See all urology providers in Nevada

Medicare billing

Part B allowed, 2024
$30,678
Medicare patients
100
Services billed
228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl34$295
Finasteride18$160

Paid to pharmacies, not to this prescriber.

Other urology in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →